Sep 22, 2026 08:30AM
Sep 22, 2026 08:30AM
Sep 10, 2026 08:30AM
Aug 28, 2026 06:00AM
Aug 28, 2026 06:00AM
Aug 14, 2026 08:30AM
Jul 9, 2026 08:30AM Quoin gets FDA clearance for Phase 2 trial of QRX003 in rare skin disease
Jul 9, 2026 08:30AM
Jun 30, 2026 08:31AM
Jun 30, 2026 08:30AM
Jun 23, 2026 08:31AM
Jun 23, 2026 08:30AM
Jun 18, 2026 08:31AM
Jun 18, 2026 08:30AM Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Jun 4, 2026 08:31AM
Jun 4, 2026 08:30AM
Jun 2, 2026 08:31AM
Jun 2, 2026 08:30AM
May 7, 2026 08:30AM
Apr 28, 2026 12:02PM
Apr 28, 2026 08:32AM Quoin Pharmaceuticals plans investigator-led studies for QRX009
Apr 28, 2026 08:30AM
Mar 26, 2026 08:30AM
Mar 25, 2026 08:31AM
Mar 25, 2026 08:30AM
Mar 11, 2026 08:30AM
Mar 11, 2026 08:30AM
Jan 27, 2026 08:31AM Quoin seeks orphan drug status for QRX003 in Japan
Jan 27, 2026 08:30AM
Jan 20, 2026 08:30AM
Nov 11, 2025 08:31AM
Nov 11, 2025 08:30AM
Nov 6, 2025 08:30AM
Oct 21, 2025 08:30AM
Oct 21, 2025 08:30AM Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
Oct 10, 2025 09:25AM
Oct 10, 2025 09:24AM
Aug 7, 2025 08:30AM
Jun 26, 2025 08:30AM
Jun 24, 2025 08:34AM
Jun 24, 2025 08:30AM
May 22, 2025 07:31AM Quoin Pharmaceuticals Ltd (QNRX) Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
May 22, 2025 07:30AM
May 13, 2025 08:00AM
Apr 10, 2025 07:30AM
Mar 25, 2025 07:31AM
Mar 25, 2025 07:30AM
Mar 13, 2025 07:30AM
Mar 4, 2025 07:30AM Quoin Pharmaceuticals (QNRX) Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Mar 4, 2025 07:30AM

331,654 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All